JSC “Rafarma” is an integrated pharmaceutical production site designed and operating in compliance with the requirements of the GMP EU. “Rafarma” project is an implementation of the Strategy “Pharma 2020”. It is on the List of perspective projects in the pharmaceutical and medical industry of Ministry of Industry and Trade RF.
Antibiotics and antineoplastics are the basis of the product portfolio of the company. Besides that, “Rafarma” manufactures oral sugar-lowering medicines, cardiovascular drugs, anti-TB drugs and medicines of other pharmacological groups.
Integrated manufacturing cycle of cephalosporins, antibiotics non-β-lactam, antineoplastics and medicines of other pharmacological groups is carried out in 5 separate sections. They are equipped with closed water-treatment systems and closed-circuit ventilation.
Home based R&D facilities carry out autonomous research activities and develop original medicines. The pilot plant is located in the Category “D” rooms to develop industrial prototypes of medicines for clinical trials and pharmacological monitoring, scale R&D developments and work out the technology for industrial production of new products.
Equipment manufactured by major European companies is installed at “Rafarma” facilities to produce almost all dosage forms of medicines. Manufacturing capacity (per year): 1.5 billion tablets, 180 million hard gelatin capsules, 62.5 million injection vials, 18 million sachets, 7.5 million vials of suspensions, 0.4 million suppository packages, 0.3 million packs of granules, 1.6 million packs gels, 0.65 million packs of solutions, 0.5 million packs of lyophilizates per year.